Drug intelligence / Profile preview

REX-003

Development stage: Preclinical
Lead developer: Alaya.bio
Modality: Cell Therapies
Administration: Intramuscular, Intra-arterial

Overview

**REX-003** is a cell replacement therapy developed by Ixaka Ltd. for the treatment of critical limb-threatening ischemia (CLTI), particularly in diabetic patients. It consists of an autologous cell-based product derived from bone marrow mononuclear cells (BM-MNCs), administered to promote revascularization, improve blood flow, heal ischemic ulcers, and alleviate chronic ischemic rest pain through paracrine mechanisms that enhance vascular density and arteriogenesis without significant cell translocation to other organs.[3][5]

Beyond the preview

Go deeper on REX-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REX-003.

Explore the full profile